7.5亿元!君实生物引进两款双靶点融合蛋白11月19日晚间,君实生物宣布将新引进两款双靶点融合蛋白在大中华区的权益,但因涉及商业敏感信息和商业秘密,关于交易对方及具体的产品信息,君实生物方面目前未有更多的披露。据君实生物与许可方签署的许可协议,许可方授予公司在大中华区(包括中国大陆、香港特别行政区、澳门特别行政区及台湾地区)内开发、制造、使用、进口、出口、销售和以其他任何方式商业化两款双靶点融合...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.